Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Completed · Phase 2
Conditions studied: Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
In brief
This phase II trial is studying how well ixabepilone works in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop cancer cells from dividing so they stop growing or die.
Key facts
- Study ID
- NCT00058019
- Run by
- National Cancer Institute (NCI)
- People needed
- 51
- Starts
- 2003-02-01
- Expected to finish
- 2010-08-01
- Last updated by the study team
- 2014-05-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following cellular types:
- Grade III follicular center
- Diffuse large B-cell
- Mantle cell
- Primary mediastinal B-cell
- Burkitt's
- High-grade B-cell (Burkitt-like)
- Anaplastic large cell of 1 of the following subtypes:
- CD30-positive
- T-cell
- Null cell
- Hodgkin's-like
- Relapsed or refractory disease after prior standard chemotherapy, meeting criteria for 1of the following cohorts:
- Cohort 1 (relapsed but chemosensitive): Prior complete response (CR) or partial response (PR) lasting at least 4 weeks after the most recent prior therapy
- Cohort 2 (refractory): Stable disease or less than a PR after the most recent prior therapy
- No progressive disease after the most recent prior therapy
- Measurable disease
- At least 1 bidimensionally measurable lesion at least 10 mm by conventional techniques or clinical exam
- Ineligible for or unwilling to undergo hematopoietic stem cell transplantation
- Patients requiring debulking prior to transplant allowed
- No known CNS involvement by lymphoma
- Prior CNS disease that has been successfully treated in patients with relapsed disease exclusively outside of the CNS may be allowed by the principal investigator
- Performance status - ECOG 0-2
- More than 3 months
- WBC at least 3,000/mm\^3
Where it is running
- University of Chicago — Chicago, Illinois, United States
- M D Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.